Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine

Charungthai Dejthevaporn, Suppachok Wetchaphanphesat, Teeratorn Pulkes, Sasivimol Rattanasiri, Andrew G. Engel, Rawiphan Witoonpanich

Research output: Contribution to journalArticlepeer-review


The slow-channel congenital myasthenic syndrome is an autosomal dominant neuromuscular disorder caused by mutations in different subunits of the acetylcholine receptor. Fluoxetine, a common antidepressant and long-lived open-channel blocker of acetylcholine receptor, has been reported to be beneficial in the slow-channel congenital myasthenic syndrome. Here we report a prospective open label study of fluoxetine treatment in some affected members of a Thai family with slow-channel congenital myasthenic syndrome caused by a novel p.Gly153Ala (c.518G > C) mutation in CHRNA1 in the AChR α subunit. These patients showed significant clinical improvement following fluoxetine treatment but their respiratory function responded variably.

Original languageEnglish (US)
Pages (from-to)85-89
Number of pages5
JournalJournal of Clinical Neuroscience
StatePublished - Feb 2022


  • Fluoxetine
  • Slow-channel congenital myasthenic syndrome
  • Thai
  • Treatment

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)


Dive into the research topics of 'Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine'. Together they form a unique fingerprint.

Cite this